Cadrenal Therapeutics Launches Strategic Process to Maximize Asset Value

Key Facts

1Cadrenal Therapeutics' Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.

2The company retained Tungsten Advisors to lead the strategic process focused on its orphan thrombo-inflammatory therapeutics.

Cadrenal Therapeutics' Board of Directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio. According to a statement on GlobeNewswire, the company retained Tungsten Advisors to lead the process, which focuses on its orphan thrombo-inflammatory therapeutics.

CVKD closed at $0.99 on October 6, 2026, with the stock reaching a session high of $1.05 and a low of $0.9004. The strategic review aims to leverage the company's late-stage biopharmaceutical assets as it explores alternatives to enhance shareholder value.